Becker's Healthcare April 2, 2024
Medicare total spending hit $5.7 billion in 2022 after rebates for GLP-1 drugs such as Ozempic, Wegovy and Mounjaro, up from $57 million in 2018, according to a March 22 KFF analysis.
While Medicare is not allowed under existing law to cover the drugs for weight loss, Medicare Part D plans can cover them for other medically accepted indications, such as reducing cardiovascular risk, according to a recent CMS memo.
Medicare Part D authorized use coverage of GLP-1 drugs could point to higher spending, especially as policymakers look at legislation that...
Today's Sponsors
Today's Sponsor